Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.

BMS builds case ahead of FDA verdict The disappointing run of data with omecamtiv is in contrast to that of Bristol-Myers Squibb with its cardiac myosin inhibitor mavacamten. That drug is also ...

Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset aficamten. Read more here.

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...